title: A high-throughput-compatible FRET-based platform for identification and characterization of botulinum neurotoxin light chain modulators.
abstract: Botulinum neurotoxin (BoNT) is a potent and potentially lethal bacterial toxin that binds to host motor neurons, is internalized into the cell, and cleaves intracellular proteins that are essential for neurotransmitter release. BoNT is comprised of a heavy chain (HC), which mediates host cell binding and internalization, and a light chain (LC), which cleaves intracellular host proteins essential for acetylcholine release. While therapies that inhibit toxin binding/internalization have a small time window of administration, compounds that target intracellular LC activity have a much larger time window of administrations, particularly relevant given the extremely long half-life of the toxin. In recent years, small molecules have been heavily analyzed as potential LC inhibitors based on their increased cellular permeability relative to larger therapeutics (peptides, aptamers, etc.). Lead identification often involves high-throughput screening (HTS), where large libraries of small molecules are screened based on their ability to modulate therapeutic target function. Here we describe a FRET-based assay with a commercial BoNT/A LC substrate and recombinant LC that can be automated for HTS of potential BoNT inhibitors. Moreover, we describe a manual technique that can be used for follow-up secondary screening, or for comparing the potency of several candidate compounds.
authors.affiliation: Department of Chemistry, The Scripps Research Institute.
authors.forename: Dejan
authors.initials: D
authors.lastname: Caglič
authors.forename: Kristin M
authors.initials: KM
authors.lastname: Bompiani
authors.forename: Michelle C
authors.initials: MC
authors.lastname: Krutein
authors.forename: Petr
authors.initials: P
authors.lastname: Čapek
authors.forename: Tobin J
authors.initials: TJ
authors.lastname: Dickerson
mesh_terms: D019274:Botulinum Toxins, Type A / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000276:immunology; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D031541:Fluorescence Resonance Energy Transfer / Q000379:methods*; D057166:High-Throughput Screening Assays / Q000379:methods*; D054852:Small Molecule Libraries / Q000494:pharmacology*; D050825:Synaptosomal-Associated Protein 25 / Q000378:metabolism
chemical_list: D054852:Small Molecule Libraries; D050825:Synaptosomal-Associated Protein 25; D019274:Botulinum Toxins, Type A